|1.||Ohori, Makoto: 2 articles (06/2008 - 01/2007)|
|2.||Panaampon, Jutatip: 1 article (08/2014)|
|3.||Kooptiwut, Suwattanee: 1 article (08/2014)|
|4.||Noisakran, Sansanee: 1 article (08/2014)|
|5.||Srisawat, Chatchawan: 1 article (08/2014)|
|6.||Yenchitsomanus, Pa-Thai: 1 article (08/2014)|
|7.||Morchang, Atthapan: 1 article (08/2014)|
|8.||Limjindaporn, Thawornchai: 1 article (08/2014)|
|9.||Suttitheptumrong, Aroonroong: 1 article (08/2014)|
|10.||Sirimontaporn, Aunchalee: 1 article (08/2014)|
06/01/2008 - "FR180204, an ERK inhibitor, has been shown to be effective against mouse collagen-induced arthritis, a representative animal model of RA. "
01/01/2007 - "FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice."
01/01/2007 - "In this paper, we investigated the effect of FR180204 on collagen-induced arthritis (CIA) in DBA/1 mice, an animal model of rheumatoid arthritis (RA) mediated by type II collagen (CII)-reactive T cells and anti-CII antibodies. "
|5.||Cardiomegaly (Heart Hypertrophy)
12/01/2011 - "ISO-induced cardiac hypertrophy and Erk1/2 activation in Pak-1-KO/ISO were attenuated when the selective Erk1/2 inhibitor FR180204 was administered. "
12/01/2011 - "Wild-type (WT) and Pak-1-knockout (Pak-1-KO) mice were randomized into six groups to receive either ISO, saline (CTRL), or ISO and FR180204, a selective inhibitor of Erk1/2. Echocardiography revealed that hearts of the Pak-1-KO/ISO group had increased LV fractional shortening, reduced LV chamber volume in diastole and systole, increased cardiac hypertrophy, and enhanced transmitral early filling deceleration time, compared to all other groups. "
|2.||Caspase 3 (Caspase-3)
|3.||Collagen Type II (Type II Collagen)